Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers.
The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA.
The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.
Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 25 | -0.40 Decreased by -3.90 K% | -0.60 Increased by +33.33% |
| Oct 31, 24 | -1.00 Decreased by -1.90 K% | -1.20 Increased by +16.67% |
| Jul 31, 24 | 0.00 Increased by +109.25% | -0.04 Increased by +109.25% |
| May 1, 24 | -0.02 Increased by +50.00% | -0.03 Increased by +33.33% |
| Feb 29, 24 | -0.01 Decreased by -150.00% | -0.03 Increased by +66.67% |
| Nov 1, 23 | -0.05 Decreased by -400.00% | -0.04 Decreased by -25.00% |
| Aug 2, 23 | -0.04 Increased by +63.64% | -0.04 |
| May 3, 23 | -0.04 Increased by +50.00% | -0.03 Decreased by -33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 62.31 M Decreased by -17.33% | -48.62 M Decreased by -733.74% | Decreased by -78.03% Decreased by -908.46% |
| Sep 30, 24 | 42.30 M Decreased by -35.97% | -25.13 M Decreased by -30.15% | Decreased by -59.42% Decreased by -103.26% |
| Jun 30, 24 | 67.57 M Decreased by -15.72% | 1.52 M Increased by +108.67% | Increased by +2.25% Increased by +110.28% |
| Mar 31, 24 | 56.49 M Decreased by -34.30% | -9.95 M Increased by +39.57% | Decreased by -17.61% Increased by +8.02% |
| Dec 31, 23 | 75.36 M Decreased by -16.49% | -5.83 M Decreased by -781.23% | Decreased by -7.74% Decreased by -915.75% |
| Sep 30, 23 | 66.06 M Decreased by -26.50% | -19.31 M Decreased by -275.70% | Decreased by -29.23% Decreased by -411.19% |
| Jun 30, 23 | 80.17 M Decreased by -15.11% | -17.56 M Increased by +74.90% | Decreased by -21.90% Increased by +70.43% |
| Mar 31, 23 | 85.97 M Decreased by -9.15% | -16.46 M Increased by +47.85% | Decreased by -19.15% Increased by +42.60% |